galantamine has been researched along with Brain Vascular Disorders in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (24.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Yamashita, T; Zhai, Y | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Kim, S; Ku, BD; Kwon, JC; Lee, AY; Lee, JH; Moon, SY; Park, JJ; Park, KW; Shim, YS | 1 |
| Dartigues, JF; Everitt, B; Feldman, HH; Kavanagh, S; Pirttila, T; Schwalen, S; Van Baelen, B | 1 |
| Chankrachang, S; Nidhinandana, S; Phanthumchinda, K; Poungvarin, N; Praditsuwan, R; Senanarong, V; Thavichachart, N | 2 |
| Marder, K | 1 |
| Kertesz, A | 1 |
| Erkinjuntti, T | 1 |
| Geerts, H; Grantham, C | 1 |
| Bowler, JV | 1 |
| Bullock, R; Damaraju, CV; Erkinjuntti, T; Kurz, A; Lilienfeld, S; Small, GW | 1 |
| Erkinjuntti, T; Kurz, A; Lilienfeld, S; Small, G | 1 |
| LUDIANSKII, EA | 1 |
| MOIRAGHI, P | 1 |
| Damaraju, CR; Erkinjuntti, T; Kurz, AF; Lilienfeld, S; Small, GW | 1 |
| Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G | 1 |
| Duaso, E; Formiga, F; Fort, I; Pérez-Castejón, JM; Riu, S; Ruiz, D | 1 |
| Bär, KJ; Boettger, MK; Mentzel, HJ; Sauer, H; Seidler, N; Terborg, C | 1 |
| Brashear, R; Bullock, R; Erkinjuntti, T; Gauthier, S; Hammond, G; Kurz, A; Schwalen, S; Zhu, Y | 1 |
| Bullock, R; Damaraju, CV; Erkinjuntti, T; Gauthier, S; Kurz, A; Lilienfeld, S | 1 |
| Kostiuchenko, VG; Mankovskiĭ, NB; Penek, NV | 1 |
| Göpel, W | 1 |
| Batskusheb, S; Mtsmkob, B | 1 |
| Cecchini, M | 1 |
2 review(s) available for galantamine and Brain Vascular Disorders
| Article | Year |
|---|---|
Treatment options: the latest evidence with galantamine (Reminyl).
Topics: Alzheimer Disease; Cerebrovascular Disorders; Dementia, Vascular; Endpoint Determination; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic | 2002 |
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease.
Topics: Aged; Cerebrovascular Disorders; Cholinergic Agents; Clinical Trials as Topic; Dementia, Vascular; Galantamine; Humans; Parasympathetic Nervous System; Synaptic Transmission | 2002 |
12 trial(s) available for galantamine and Brain Vascular Disorders
| Article | Year |
|---|---|
Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Neuropsychological Tests; Nimodipine; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vasodilator Agents | 2014 |
Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cerebrovascular Disorders; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Middle Aged; Surveys and Questionnaires; Treatment Outcome | 2017 |
Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cohort Studies; Female; Galantamine; Humans; Male; Middle Aged; Thailand | 2009 |
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Galantamine; Humans; Treatment Outcome | 2002 |
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Double-Blind Method; Galantamine; Humans; Nausea; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Vomiting | 2002 |
An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male | 2003 |
Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Psychiatric Status Rating Scales; Treatment Outcome | 2003 |
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Galantamine; Humans; Male; Neuropsychological Tests | 2003 |
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Drug Administration Schedule; Female; Galantamine; Humans; Male; Nootropic Agents; Treatment Outcome | 2006 |
Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cerebrovascular Disorders; Cognition; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Psychomotor Performance; Risk Assessment | 2008 |
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Treatment Outcome | 2002 |
[Nivaline in neurological therapy (report of 100 cases)].
Topics: Adult; Aged; Central Nervous System Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Galantamine; Humans; Injections, Subcutaneous; Male; Neuromuscular Diseases; Paralysis; Peripheral Nervous System Diseases | 1971 |
11 other study(ies) available for galantamine and Brain Vascular Disorders
| Article | Year |
|---|---|
Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cerebrovascular Disorders; Disease Models, Animal; Disease Progression; Galantamine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotective Agents; Neurovascular Coupling; Nootropic Agents; Receptors, Nicotinic | 2016 |
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Female; Follow-Up Studies; Galantamine; Humans; Institutionalization; Long-Term Care; Male; Nursing Homes; Severity of Illness Index; Statistics as Topic; Time Factors; Treatment Outcome | 2009 |
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Piperidines; Severity of Illness Index; Terminology as Topic; Treatment Outcome | 2003 |
[ON THE USE OF ANTICHOLINESTERASE AGENTS IN THE TREATMENT OF NEUROLOGICAL DISEASES].
Topics: Cerebrovascular Disorders; Cholinesterase Inhibitors; Drug Therapy; Erectile Dysfunction; Galantamine; Humans; Male; Muscular Diseases; Nervous System Diseases; Neuritis; Peripheral Nervous System Diseases; Sciatic Nerve | 1964 |
[Nivaline therapy in residual hemiparesis from cerebral vascular disorders].
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Galantamine; Humans; Intracranial Arteriosclerosis; Paralysis; Paresis | 1962 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic | 2004 |
[Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Male; Piperidines; Risperidone | 2006 |
Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy.
Topics: Acetylcholinesterase; Adult; Aged; Alzheimer Disease; Carbon Dioxide; Case-Control Studies; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Female; Galantamine; Humans; Male; Middle Aged; Nervous System; Spectroscopy, Near-Infrared; Ultrasonography, Doppler | 2007 |
[Effectiveness of gammalon and anticholinesterase preparations in the restorative and residual periods of ischemic stroke in old age].
Topics: Age Factors; Aged; Aminobutyrates; Cerebrovascular Disorders; Drug Evaluation; Female; Galantamine; gamma-Aminobutyric Acid; Humans; Ischemia; Male; Middle Aged | 1976 |
[Nivalin in rehabilitation of residual paralysis after cerebrovascular accidents].
Topics: Adult; Aged; Cerebrovascular Disorders; Drug Synergism; Female; Galantamine; Humans; Male; Middle Aged; Paralysis; Time Factors; Triazines | 1970 |
[Treatment of the motor sequelae of cerebral vascular diseases with galanthamine hydrobromide. Clinical report].
Topics: Cerebrovascular Disorders; Galantamine; Hemiplegia; Humans; Movement Disorders | 1966 |